Combination of Deep-Learning Models Provides Significant Risk-Assessment of Survival in Pancreatic Cancer Patients, Holding Promise as a Prognostic Technology

Advertisement

BEGIN ARTICLE PREVIEW:

NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, presented virtually with NantOmics and ImmunityBio

END ARTICLE PREVIEW

READ MORE FROM SOURCE ARTICLE